Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 6, 2003, Pages 361-366

  Sayer, Herbert G ^a   Schilling, Kristina ^a   Vogt, Tobias ^a   Blumenstengel, Kerstin ^a   Issa, Miriam Charbel ^a   Mügge, Lars Olof ^a   Kasper, Christoph ^a   Kath, Roland ^b   Höffken, Klaus ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Medizinische Klinik I   (Germany)

Author keywords

Adriamycin; Autologous stem cell transplantation; High dose chemotherapy; Metastatic breast cancer; Paclitaxel

Indexed keywords

ANALGESIC AGENT; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ARTICLE; BLOOD TOXICITY; BONE LESION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TOXICITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKOCYTE; LIVER TOXICITY; METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; THIOTEPA; TREATMENT OUTCOME;

EID: 0042659719     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0449-3     Document Type: Article

References (19)

1. Antman KH, Rowlings PA, Vaughan WP, et al (1997) High-dose chemotherapy with autologous hematopoetic stem cell support for breast cancer in North America. J Clin Oncol 15:1870-1879
2. Stadtmauer EA, O'Neill A, Goldstein LJ, et al (2000) Conventional dose chemotherapy compared with high dose chemotherapy plus autologous hematopoetic stem-cell transplantation. N Engl J Med 324:1069-1076
3. Lotz JP, Cure H, Janvier H, et al (1999) High-dose chemotherapy (HD-CT) with hematopoetic stem cell transplantation (HSCT) for metastatic breast cancer (MBC): results of the French protocol PEGASE 04. Proc Am Soc Clin Oncol 18:161 [abstr]
4. Mandan B, Broadwater G, Rubin P, et al (2000) Improved survival with consolidation high-dose cyclophosphamide, cisplatin and carmustin (HD-CPB) compared with observation in women with metastatic breast cancer (MBC) and only bone metastases treated with induction adriamycin, 5-fluorouracil, and methotrexate (AFM): a phase III prospective randomized comparative trial. Proc Am Soc Clin Oncol 19:184 [abstr]
5. Berry DA, Broadwater G, Klein JP, et al (2002) High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 20:743-750
6. Tomiak E, Piccart M, Mignolet B, et al (1996) Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC Breast Group study. Eur J Cancer 32:1876-1887
7. Perez EA, Vogel CL, Irwin DA, Kirsher JJ, Patel R (2001) Multicenter Phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223
8. Budmann DR, Berry DA, Cirrincione CT, et al (1998) Dose and dose-intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia Group B. J Natl Cancer Inst 90:1205-1211
9. Fumoleau P, Bremond A, Kerbrat P, et al (1999) Better outcome of premenopausal node positive breast cancer patients treated with six cycles vs. three cycles of adjuvant chemotherapy: eight year follow up results of FASG01. Proc Am Soc Clin Oncol 18:67 [abstr 252]
10. Nabholtz JM, Gelmon K, Bontenbal M, et al (1996) Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867
11. Paridaens R, Biganzoli L, Bruning P, et al (2000) Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18:724-733
12. Sayer HG, Kath R, Vogt T, et al (2000) Efficacy of a fixed low dose G-CSF in reconstitution of hematopoiesis after double autologous blood stem cell transplantation in solid tumors Blood 96 [Suppl]:11
13. Vogel W, Kunert C, Blumenstengel K, et al (1998) Correlation between granulocyte/macrophage-colony-forming units and CD-34 + cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize periheral blood progenitor cell. J Cancer Res Clin Oncol 24:341-345
14. Rahman Z, Champlin R, Rondon G, et al (1997) Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol 24 [Suppl 17]:77-80
15. Gianni L (2002) High-dose chemotherapy for breast cancer: any use for it? Ann Oncol 13:650-652
16. Gianni L, Munzone E, Capri G, et al (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 11:2688-2699
17. O'Shaughnessy J, Miles D, Vukelja S, et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812-2823
18. de Magalhaes-Siverman, Bloom E, Lembersky B, et al (1997) High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as intial therapy for metastatic breast cancer. Clin Cancer Research 3:193-197
19. Schmid P, Samonigg H, Nitsch T, et al (2002) Randomized trial of upfront tandem high dose chemotherapy(HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 21:171[abstr]